ABI-112

ABI-112 is an adeno-associated virus (AAV)-based gene therapy candidate being developed by Avirmax Biopharma for the treatment of neovascular retinal diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and polypoidal choroidal vasculopathy (PCV). The therapy utilizes a proprietary AAV vector engineered for efficient retinal transduction following intravitreal injection. ABI-112 is designed to deliver a therapeutic transgene that enables the long-term intraocular production of a protein—typically an anti-VEGF agent—to inhibit pathological angiogenesis and vascular leakage. By providing a sustained source of therapeutic protein, ABI-112 aims to reduce the treatment burden associated with frequent intravitreal injections of standard-of-care anti-VEGF therapies. The program is currently in the preclinical stage of development.